Business
IceCure Medical Reports Financial Results as of and for the first Nine Months of 2021 and Recent Corporate Developments
CAESAREA, Israel, Nov. 23, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of next-generation,
About this update from Icecure Medical Ltd.
[{"type":"text","content":"CAESAREA, Israel, Nov. 23, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (\"IceCure\" or the \"Company\"), developer of next-generation, minimally-invasive cryoablation technology with ProSense® that destroys tumors by freezing as an alternative to surgical tumor removal, today reported its financial results as of and for the nine-month period ended September 30, 2021.\nRecent Corporate Developments\nOn September 13th, IceCure announced the first peer-reviewed article of its ICE3 Clinical Trial \"Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial\". The article was published in the Annals of Surgical Oncology by the lead author Dr. Richard Fine, M.D., FACS, an ICE3 investigator who serves as Program Director of the Breast Surgical Oncology Fellowship and as Director of Research and Education at the West Comprehensive Breast Center in Germantown, Tennessee, as the lead author. On October 12th, the Company submitted an amendment to the registration certificate for the IceSense3® system to China's National Medical Products Administration (\"NMPA\"), which, if approved, would allow the disposable IceSense3 Cryoprobes to be sold for commercial procedures in mainland China. Approval of the amendment is expected by the end of 2022, which would be followed by a commercial sales program launch in China in early 2023. On October 20th, IceCure announced an expansion of the Company's global distribution network with an initial distribution agreement in Poland with Mobile SCANMED Systems SP. z o.o. (\"Mobile SCANMED Systems\") to exclusively sell the ProSense® Cryoablation System and disposables. On November 1st, the Company announced a peer-reviewed publication, \"VAB and MRI Following Percutaneous Ultra-Sound Guided Cryoablation for Primary Early-Stage Breast Cancer: A Pilot Study in Japan\", that was published in the Journal of Cancer Therapy by lead author Dr. Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery Breast and Imaging Center, St. Marianna University School of Medicine, Japan. The published data from the independent study demonstrated that percutaneous cryoablation presents a potential substitute for lumpectomy of breast tumors","length":3058,"tagName":"div"}]